<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180608</url>
  </required_header>
  <id_info>
    <org_study_id>vubmtmoensLIIRA</org_study_id>
    <nct_id>NCT01180608</nct_id>
  </id_info>
  <brief_title>Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain</brief_title>
  <official_title>Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain in Patients With Diabetic Polyneuropathy Using Proton MR Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moens Maarten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Functional Imaging of the therapeutic effect of Pregabalin in treatment for neuropathic pain
      in patients with Diabetic Polyneuropathy using proton Magnetic Resonance Spectroscopy (MRS):

      The aim of our study is to investigate the effect of Pregabalin as a treatment for
      neuropathic pain in a homogeneous study population, using proton MRS (1H MRS) focusing on
      four regions of interest (bilateral thalami, rostral anterior cingulated cortex (rACC) and
      dominant dorsolateral prefrontal cortex (DLPC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      spectrum measurements at: thalamus left thalamus right rostral anterior cingulated cortex
      dominant dorsolateral prefrontal cortex

      measurements: gamma-aminobutyric acid (GABA) glutamate (Glu) glutamine (Gln)
      N-acetylaspartate (NAA) Choline-containing compounds (Cho) Creatine plus phophocreatine
      (total creatine: Cr) Myo-inositiol (Ins) Choline (Cho) Glucose (Glc) Lactate (Lac)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cerebral neurobiological effect of pregabaline as treatment for neuropathic pain</measure>
    <time_frame>1 year</time_frame>
    <description>We will measure changes in neurotransmitter levels in the brain (gamma-aminobutyric acid (GABA) glutamate (Glu) glutamine (Gln) N-acetylaspartate (NAA) Choline-containing compounds (Cho) Creatine plus phophocreatine (total creatine: Cr) Myo-inositiol (Ins) Choline (Cho) Glucose (Glc) Lactate (Lac)) before and after treatment with pregabaline. Specific interest in ratio GABA/Gln and GABA/Glu: relationship between inhibitory and excitatory neurotransmittors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cerebral neurobiological changes in relationship with dose dependent therapeutic effect of treatment with pregabaline</measure>
    <time_frame>1 year</time_frame>
    <description>A possible dose dependent effect of treatment with Pregabalin on cerebral neurochemical changes (gamma-aminobutyric acid (GABA) glutamate (Glu) glutamine (Gln) N-acetylaspartate (NAA) Choline-containing compounds (Cho) Creatine plus phophocreatine (total creatine: Cr) Myo-inositiol (Ins) Choline (Cho) Glucose (Glc) Lactate (Lac)) and clinical effects (pain and quality of life scales) will be evaluated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + pregabalin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MR Spectroscopy</intervention_name>
    <description>During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:
gamma-aminobutyric acid (GABA)
glutamate (Glu)
glutamine (Gln)
N-acetylaspartate (NAA)
Choline-containing compounds (Cho)
Creatine plus phophocreatine (total creatine: Cr)
Myo-inositiol (Ins)
Choline (Cho)
Glucose (Glc)
Lactate (Lac)</description>
    <arm_group_label>Pregabalin</arm_group_label>
    <arm_group_label>placebo + pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patients with painful DPN

          -  Patient willing to provide informed consent

          -  Type 1 or type 2 diabetes with HbA1c ≤ 11%

          -  Stable antidiabetic medication for 30 days prior to randomization

          -  Duration of painful DPN ≥ 3 months

          -  Visual analogue scale (VAS) score ≥ 4

        Exclusion Criteria:

          -  Creatinine clearance ≤ 60mL/min

          -  Presence of other clinically significant or disabling chronic pain condition

          -  Active malignancy

          -  Evidence of an active disruptive psychiatric disorder or other known condition that
             might influence the perception of pain, compliance to intervention and/or ability to
             evaluate treatment outcome as determined by the investigator

          -  Life expectancy less than 1 year

          -  Existing or planned pregnancy

          -  Extreme fear for entering MRI

          -  General contraindication for MRI (pacemaker, etc…)

          -  Patients participating in other clinical trials

          -  Age &lt;18 years

          -  Prior use of potential retinotoxins

          -  Prohibited medications without proper wash-out period (&gt;7days, depending on the type
             of medication):

               -  medications and supplements commonly used for relief of neuropathic pain

               -  antiepileptics

               -  antidepressants (except for stable regiments of SSRIs for treatment of anxiety or
                  depression)

               -  NSAID
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maarten Moens, MD</last_name>
    <phone>0032478884047</phone>
    <email>mtmoens@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maarten Moens, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maarten Moens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>August 11, 2010</last_update_submitted>
  <last_update_submitted_qc>August 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Maarten Moens, MD</name_title>
    <organization>UZ Brussel</organization>
  </responsible_party>
  <keyword>neuropathic pain</keyword>
  <keyword>Diabetic Polyneuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

